semaglutide shortage ending Novo Nordisk's officially concludes in the US, spelling major threat for weight loss drug compounders compounded semaglutide fda enforcement news

When evaluating whether semaglutide might be contributing to leg cramps in an individual patient, clinicians must consider the temporal relationship between medication initiation or dose escalation and symptom onset, the presence of alternative explanations, and whether symptoms resolve with dose adjustment or discontinuation

The acquisition strengthens Gileads immuno-oncology portfolio with the addition of Forty Sevens investigational lead candidate, magrolimab, a monoclonal antibody in clinical development for the treatment of several cancers including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL)

Yeah, that was, it was very interesting

doi:10.1007/s42000-019-00093-w Van de Laar FA, Lucassen PL, Akkermans RP, et al